a Department of Anesthesiology , Queen Mary Hospital, The University of Hong Kong , Pokfulam , Hong Kong SAR.
b Faculty of Veterinary and Agricultural Sciences , The University of Melbourne , Melbourne , Australia.
Redox Rep. 2018 Dec;23(1):1-24. doi: 10.1080/13510002.2017.1324381. Epub 2017 May 17.
This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy.
A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress.
Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression.
Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..
这是一篇叙述性综述，探讨了用于糖尿病治疗的药物的抗氧化特性，并讨论了这些抗氧化作用是否有助于、干扰或掩盖抗氧化治疗的效果。
使用 Web of Science、PubMed 和 Ovid 系统地搜索了关于在人类或动物中治疗糖尿病的药物的抗氧化作用的试验或观察性研究的文章。提取了数据，包括关于一定数量的受试者、接受的治疗类型（和持续时间）以及主要和次要结局的数据。主要结局是报告抗氧化剂浓度的生物标志物的变化，次要结局是报告氧化应激生物标志物的变化。
糖尿病是一种以氧化应激增加为特征的疾病。它通常伴有一系列其他代谢紊乱，包括血浆脂质升高、尿酸升高、高血压、内皮功能障碍和中心性肥胖。这篇综述表明，一些用于糖尿病治疗的药物通过清除自由基和上调抗氧化基因表达等机制具有体内和体外的抗氧化特性。
用于治疗 2 型糖尿病的药物已被证明具有抗氧化作用。
